Heron Therapeutics (AXD2) Stock Statistics & Valuation Metrics
Total Valuation
Heron Therapeutics has a market cap or net worth of CHF 43.43M. The enterprise value is CHF 187.97M.
- Market Cap
- CHF 43.43M
- Enterprise Value
- CHF 187.97M
Share Statistics
Heron Therapeutics has 189,852,310 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 189,852,310
- Owned by Insiders
- 5.64%
- Owned by Institutions
- 16.38%
Financial Efficiency
Heron Therapeutics’s return on equity (ROE) is -1.41 and return on invested capital (ROIC) is -1.59%.
- Return on Equity (ROE)
- -1.41
- Return on Assets (ROA)
- -0.08
- Return on Invested Capital (ROIC)
- -1.59%
- Return on Capital Employed (ROCE)
- -0.02
- Revenue Per Employee
- 1.21M
- Profits Per Employee
- -157.77K
- Employee Count
- 128
- Asset Turnover
- 0.61
- Inventory Turnover
- 0.45
Valuation Ratios
The current PE Ratio of Heron Therapeutics is -1.48. Heron Therapeutics’s PEG ratio is 0.01.
- PE Ratio
- -1.48
- PS Ratio
- 0.35
- PB Ratio
- 7.65
- Price to FCF
- -4.34
- Price to Operating Cash Flow
- -4.55
- PEG Ratio
- 0.01
Income Statement
In the last 12 months, Heron Therapeutics had revenue of 154.90M and earned -20.20M in profits. Earnings per share was -0.12.
- Revenue
- 154.90M
- Gross Profit
- 113.56M
- Operating Income
- -2.54M
- Pretax Income
- -20.20M
- Net Income
- -20.20M
- EBITDA
- -17.88M
- Earnings Per Share (EPS)
- -0.12
Cash Flow
In the last 12 months, operating cash flow was -11.61M and capital expenditures -529,000, giving a free cash flow of -12.13M billion.
- Operating Cash Flow
- -11.61M
- Free Cash Flow
- -12.13M
- Free Cash Flow per Share
- -0.06
Dividends & Yields
Heron Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -23.02%
- Earnings Yield
- -64.42%
Stock Price Statistics
- Beta
- -0.28
- 52-Week Price Change
- ―
- 50-Day Moving Average
- ―
- 200-Day Moving Average
- ―
- Relative Strength Index (RSI)
- ―
- Average Volume (3m)
- ―
Important Dates
Heron Therapeutics upcoming earnings date is Nov 09, 2026, Before Open (Not Confirmed).
- Last Earnings Date
- Aug 10, 2026
- Next Earnings Date
- Nov 09, 2026
- Ex-Dividend Date
- ―
Financial Position
Heron Therapeutics as a current ratio of 2.48, with Debt / Equity ratio of 981.22%
- Current Ratio
- 2.48
- Quick Ratio
- 1.51
- Debt to Market Cap
- 0.65
- Net Debt to EBITDA
- -6.26
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Heron Therapeutics has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Heron Therapeutics EV to EBITDA ratio is -6.44, with an EV/FCF ratio of -14.86.
- EV to Sales
- 1.19
- EV to EBITDA
- -6.44
- EV to Free Cash Flow
- -14.86
- EV to Operating Cash Flow
- -15.54
Balance Sheet
Heron Therapeutics has CHF 42.66M in cash and marketable securities with CHF 148.35M in debt, giving a net cash position of -CHF 105.69M billion.
- Cash & Marketable Securities
- CHF 42.66M
- Total Debt
- CHF 148.35M
- Net Cash
- -CHF 105.69M
- Net Cash Per Share
- -CHF 0.56
- Tangible Book Value Per Share
- CHF 0.04
Margins
Gross margin is 70.07%, with operating margin of -7.19%, and net profit margin of -22.52%.
- Gross Margin
- 70.07%
- Operating Margin
- -7.19%
- Pretax Margin
- -22.52%
- Net Profit Margin
- -22.52%
- EBITDA Margin
- -18.53%
- EBIT Margin
- -19.94%
Analyst Forecast
The average price target for Heron Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is Neutral
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- Neutral
- Analyst Count
- 2
- Revenue Growth Forecast
- -7.66%
- EPS Growth Forecast
- -3876.32%
Scores
- Smart Score
- 1
- AI Score
- ―